{"log_id": 6989225665412803647, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 5e-06, "average": 0.998512, "min": 0.988746}, "location": {"width": 745, "top": 213, "height": 35, "left": 185}, "words": "如果情况严重,数天后可能会进展为粘膜溃疡。绝大多数患者在给药后的第三周得以恢复"}, {"probability": {"variance": 4e-06, "average": 0.998579, "min": 0.989022}, "location": {"width": 790, "top": 251, "height": 38, "left": 223}, "words": "有时,对于患急性白血病或其他疾病或接受已知会引起胃肠道并发症药物的患者口服伊达比星"}, {"probability": {"variance": 0.000427, "average": 0.993401, "min": 0.879608}, "location": {"width": 848, "top": 290, "height": 38, "left": 184}, "words": "偶尔会发生严重的胃肠道不良反应(如穿孔或出血)。对于有出血和/或穿孔高风险的活动性胃肠道疾病"}, {"probability": {"variance": 7e-06, "average": 0.998446, "min": 0.98697}, "location": {"width": 401, "top": 336, "height": 29, "left": 185}, "words": "患者,医生必须权衡口服伊达比星的益处与风险"}, {"probability": {"variance": 4.6e-05, "average": 0.996952, "min": 0.977852}, "location": {"width": 166, "top": 421, "height": 25, "left": 185}, "words": "肝功能和/或肾功能"}, {"probability": {"variance": 0.000203, "average": 0.997377, "min": 0.906155}, "location": {"width": 797, "top": 452, "height": 33, "left": 235}, "words": "由于肝和/或肾功能损害会影响伊达比星的代谢,所以在临床治疗前及治疗过程中应常规进行肝"}, {"probability": {"variance": 0.001534, "average": 0.989396, "min": 0.791433}, "location": {"width": 849, "top": 491, "height": 34, "left": 185}, "words": "肾功能的实验室检查(使用血清胆红素和血清肌酐作为指标)。在一些II期临床试验中规定如果血清"}, {"probability": {"variance": 0.000984, "average": 0.990639, "min": 0.881971}, "location": {"width": 247, "top": 535, "height": 28, "left": 185}, "words": "胆红素和/或肌酐水平超过2"}, {"probability": {"variance": 0.001712, "average": 0.991024, "min": 0.761511}, "location": {"width": 557, "top": 529, "height": 31, "left": 477}, "words": "100ml,则禁止使用伊达比星治疗。如果胆红素水平范围在1.2到"}, {"probability": {"variance": 0.011427, "average": 0.972655, "min": 0.532012}, "location": {"width": 322, "top": 572, "height": 27, "left": 310}, "words": "其他葸环类药物通常会减少50%的剂量"}, {"probability": {"variance": 1e-06, "average": 0.9992, "min": 0.996867}, "location": {"width": 138, "top": 656, "height": 23, "left": 186}, "words": "注射部位的影响"}, {"probability": {"variance": 4e-05, "average": 0.998491, "min": 0.957951}, "location": {"width": 809, "top": 688, "height": 31, "left": 226}, "words": "小静脉注射或者反复注射同一静脉可能造成静脉硬化,按照推荐的给药流程操作可以尽可能的减"}, {"probability": {"variance": 7.4e-05, "average": 0.997361, "min": 0.962068}, "location": {"width": 336, "top": 730, "height": 25, "left": 187}, "words": "少注射部位静脉炎/血栓性静脉炎的发生"}, {"probability": {"variance": 0, "average": 0.999513, "min": 0.998322}, "location": {"width": 78, "top": 813, "height": 24, "left": 187}, "words": "药物外渗"}, {"probability": {"variance": 0.000118, "average": 0.997301, "min": 0.92842}, "location": {"width": 810, "top": 846, "height": 32, "left": 224}, "words": "伊达比星静脉注射时发生外渗会导致局部疼痛、严重组织损伤(发疱、严重的蜂窝组织炎)和坏"}, {"probability": {"variance": 2e-06, "average": 0.999176, "min": 0.992378}, "location": {"width": 517, "top": 886, "height": 31, "left": 187}, "words": "死。注射时一旦发生药液外渗的症状和体征,应立即停止注射"}, {"probability": {"variance": 3e-05, "average": 0.995281, "min": 0.984625}, "location": {"width": 138, "top": 972, "height": 24, "left": 187}, "words": "肿瘤溶解综合征"}, {"probability": {"variance": 2e-06, "average": 0.999165, "min": 0.993053}, "location": {"width": 809, "top": 1004, "height": 34, "left": 227}, "words": "使用伊达比星可能会导致高尿酸血症,其原因是伴随药物诱导的肿瘤细胞的迅速崩解而产生过度"}, {"probability": {"variance": 6e-06, "average": 0.998287, "min": 0.989741}, "location": {"width": 847, "top": 1043, "height": 34, "left": 189}, "words": "的嘌呤分解代谢(肿瘤溶解综合征)。因此在初始治疗开始后需要监测血尿酸、钾、磷酸钙、肌酐等情"}, {"probability": {"variance": 1.1e-05, "average": 0.998368, "min": 0.97896}, "location": {"width": 845, "top": 1082, "height": 32, "left": 190}, "words": "况。水化、碱化尿液、预防性使用别嘌呤醇防止高尿酸血症的出现,从而尽可能的减少肿瘤溶解综合"}, {"probability": {"variance": 0, "average": 0.999318, "min": 0.998776}, "location": {"width": 78, "top": 1128, "height": 22, "left": 191}, "words": "症的发生"}, {"probability": {"variance": 0.039958, "average": 0.776572, "min": 0.509615}, "location": {"width": 109, "top": 1143, "height": 45, "left": 897}, "words": "民药分"}, {"probability": {"variance": 5e-05, "average": 0.997315, "min": 0.971926}, "location": {"width": 261, "top": 1205, "height": 28, "left": 191}, "words": "免疫抑制效应/感染易感性增加"}, {"probability": {"variance": 0, "average": 0.892337, "min": 0.892337}, "location": {"width": 46, "top": 1189, "height": 44, "left": 1017}, "words": "诚"}, {"probability": {"variance": 2e-06, "average": 0.998968, "min": 0.991472}, "location": {"width": 790, "top": 1240, "height": 31, "left": 227}, "words": "对于接受化疗药物包括伊达比星而导致免疫妥协的患者接种活疫苗或者减毒活疫苗可能会产生"}, {"probability": {"variance": 0.000393, "average": 0.993933, "min": 0.875302}, "location": {"width": 855, "top": 1272, "height": 37, "left": 191}, "words": "重甚至致命的感染。正在接受伊达比星治疗的患者应当避免接种活疫苗。可以接种死疫苗或者灭活"}, {"probability": {"variance": 1e-06, "average": 0.999305, "min": 0.997054}, "location": {"width": 365, "top": 1320, "height": 27, "left": 192}, "words": "苗,但是对这些疫苗的免疫应答可能会降低"}, {"probability": {"variance": 0, "average": 0.995131, "min": 0.995131}, "location": {"width": 30, "top": 1314, "height": 35, "left": 967}, "words": "{"}, {"probability": {"variance": 1e-06, "average": 0.998655, "min": 0.997439}, "location": {"width": 79, "top": 1405, "height": 23, "left": 192}, "words": "生殖系统"}, {"probability": {"variance": 2.5e-05, "average": 0.996378, "min": 0.985817}, "location": {"width": 124, "top": 1532, "height": 22, "left": 554}, "words": "第7页,共11页"}, {"probability": {"variance": 0.000897, "average": 0.978703, "min": 0.908017}, "location": {"width": 76, "top": 1560, "height": 18, "left": 261}, "words": "20110201"}], "language": 3}